Articles producció científica> Medicina i Cirurgia

Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A 24-week double-blind, randomized, parallel, placebo-controlled trial

  • Datos identificativos

    Identificador: PC:1539
    Handle: https://hdl.handle.net/20.500.11797/PC1539
    Autores:
    José FrancoJudith UsallElena Huerta-RamosJavier LabadJesús CoboChristian NúñezMarta CreusGemma García ParésDaniel CuadrasEva MiquelJulio César ReyesMercedes Roca
    Resumen:
    The potential therapeutic utility of estrogens in schizophrenia is increasingly being recognized. Raloxifene, a selective estrogen receptor modulator, appears to act similarly to estrogens on dopamine and serotonin brain systems. One previous trial by our team found that raloxifene was useful to improve negative, positive, and general psychopathological symptoms, without having the negative side effects of estrogens. In this study, we assess the utility of raloxifene in treating negative and other psychotic symptoms in postmenopausal women with schizophrenia exhibiting prominent negative symptoms. This was a 24-week, randomized, parallel, double-blind, placebo-controlled study. Patients were recruited from the inpatient and outpatient departments of Parc Sanitari Sant Joan de Déu, Hospital Universitari Institut Pere Mata, and Corporació Sanitària Parc Taulí. Seventy postmenopausal women with schizophrenia (DSM-IV) were randomized to either adjunctive raloxifene (38 women) or adjunctive placebo (32 women). Psychopathological symptoms were assessed at baseline and at weeks 4, 12, and 24 with the Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS). The addition of raloxifene (60 mg/d) to regular antipsychotic treatment significantly reduced negative (P = .027), general (P = .003), and total symptomatology (P = .005) measured with the PANSS during the 24-week trial, as compared to women receiving placebo. Also Alogia SANSS subscale improved more in the raloxifene (P = .048) than the placebo group. In conclusion, raloxifene improved negative and general psychopathological symptoms, compared with antipsychotic medication alone, in postmenopausal women with schizophrenia. These data replicate our previous results with a lar

  • Otros:

    Autor según el artículo: José Franco; Judith Usall; Elena Huerta-Ramos; Javier Labad; Jesús Cobo; Christian Núñez; Marta Creus; Gemma García Parés; Daniel Cuadras; Eva Miquel; Julio César Reyes; Mercedes Roca
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: FRANCO VÁSQUEZ, JOSÉ GABRIEL; Judith Usall; Elena Huerta-Ramos; Javier Labad; Jesús Cobo; Christian Núñez; Marta Creus; Gemma García Parés; Daniel Cuadras; Eva Miquel; Julio César Reyes; Mercedes Roca
    Palabras clave: SERM negative symptoms estrogen
    Resumen: The potential therapeutic utility of estrogens in schizophrenia is increasingly being recognized. Raloxifene, a selective estrogen receptor modulator, appears to act similarly to estrogens on dopamine and serotonin brain systems. One previous trial by our team found that raloxifene was useful to improve negative, positive, and general psychopathological symptoms, without having the negative side effects of estrogens. In this study, we assess the utility of raloxifene in treating negative and other psychotic symptoms in postmenopausal women with schizophrenia exhibiting prominent negative symptoms. This was a 24-week, randomized, parallel, double-blind, placebo-controlled study. Patients were recruited from the inpatient and outpatient departments of Parc Sanitari Sant Joan de Déu, Hospital Universitari Institut Pere Mata, and Corporació Sanitària Parc Taulí. Seventy postmenopausal women with schizophrenia (DSM-IV) were randomized to either adjunctive raloxifene (38 women) or adjunctive placebo (32 women). Psychopathological symptoms were assessed at baseline and at weeks 4, 12, and 24 with the Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS). The addition of raloxifene (60 mg/d) to regular antipsychotic treatment significantly reduced negative (P = .027), general (P = .003), and total symptomatology (P = .005) measured with the PANSS during the 24-week trial, as compared to women receiving placebo. Also Alogia SANSS subscale improved more in the raloxifene (P = .048) than the placebo group. In conclusion, raloxifene improved negative and general psychopathological symptoms, compared with antipsychotic medication alone, in postmenopausal women with schizophrenia. These data replicate our previous results with a larger sample and a longer follow-up. Trial registration: NCT01573637.
    Grupo de investigación: Grup d'Investigació en Psiquiatria
    Áreas temáticas: Ciències de la salut Ciencias de la salud Health sciences
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 0586-7614
    Identificador del autor: orcid.org/0000-0001-9255-8084; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D
    Fecha de alta del registro: 2016-05-19
    Página final: 317
    Volumen de revista: 42
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2016
    Página inicial: 309
    Tipo de publicación: Article Artículo Article

  • Palabras clave:

    Antihormones
    Estrògens
    Esquizofrènia -- Tractament
    SERM
    negative symptoms
    estrogen
    Ciències de la salut
    Ciencias de la salud
    Health sciences
    0586-7614

  • Documentos:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar